Recent 8-K filings for CTOR

• June 1, 2026, 4:30 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

  24% ORR (5 partial responses) among 21 efficacy-evaluable patients with recurrent/refractory gynecologic malignancies.

• May 15, 2026, 4:44 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing

  Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.

• May 6, 2026, 7:59 PM ET debt materiality 0.75 positive item 1.01item 2.03item 3.02item 8.01item 9.01 ◈ Material Agreements

  Citius Oncology secures up to $36.5M in debt and warrant exercise proceeds

  Warrant inducement yields ~$11.5M gross from exercise of 12.8M shares at $0.90; new warrants for 25.6M shares at $0.90.

• April 29, 2026, 7:59 PM ET other material materiality 0.50 positive item 8.01item 9.01

  Citius Oncology ships first international LYMPHIR order to Europe via NPPs

  Initial shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through regional distribution partner.

• April 28, 2026, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

  Citius Oncology receives Nasdaq deficiency notice for falling below $1.00 bid price

  Nasdaq notified Citius Oncology on April 22, 2026 that bid price closed below $1.00 for 30 consecutive business days.

• March 31, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Citius Oncology reports early LYMPHIR launch traction; 83% of target accounts in formulary review

  83% of target accounts have added or are actively progressing LYMPHIR through formulary review.

• March 10, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Citius Oncology reports positive Phase 1 topline data for LYMPHIR + pembrolizumab in gynecologic cancers

  24% objective response rate (ORR) and 48% clinical benefit rate (CBR) among 21 evaluable patients.

• March 4, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology reports positive Phase 1 data for LYMPHIR prior to CAR-T in DLBCL

  Overall response rate 86% (57% complete response, 29% partial response) at one month in 14 patients.

• February 13, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Citius Oncology reports first revenue of $3.9M from LYMPHIR launch; net loss narrows to $5.5M

  Revenue of $3.9M for Q1 FY2026 ended Dec 31, 2025, first reported sales following December 2025 commercial launch of LYMPHIR.

• December 23, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Citius Oncology reports FY 2025 net loss of $24.8M; launches LYMPHIR in U.S.

  Net loss of $24.8M ($0.34 per share) vs $21.1M ($0.31) in FY 2024, driven by pre-commercial investment.

• December 10, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Citius Oncology raises $18M in registered direct & private placement; funds LYMPHIR launch

  Gross proceeds ~$18M from sale of 1,284,404 shares at $1.09 + 15,229,358 pre-funded warrants at $1.0899 per unit.

• December 1, 2025, 6:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Citius Oncology launches LYMPHIR, first commercial product, for CTCL

  LYMPHIR (denileukin diftitox-cxdl) now available nationwide via specialty distributors.

• October 27, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Citius Oncology shareholders approve doubling of stock incentive plan shares to 30M

  At Oct 27 annual meeting, shareholders elected Class I directors Myron Holubiak and Joel Mayersohn for three-year terms.

• October 23, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Citius Oncology corporate presentation confirms LYMPHIR launch in Q4 2025; $400M+ market

  LYMPHIR (denileukin diftitox) FDA-approved Aug 2024 for relapsed/refractory CTCL; first new systemic therapy since 2018.

• September 19, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02item 5.02item 9.01

  Citius Oncology doubles share reserve to 30M under 2024 equity plan; issues 360K warrants

  Board approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.

• September 10, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Citius Oncology raises $9.0M in registered direct offering and warrant private placement

  Sold 5,142,858 shares and warrants for 5,142,858 shares at $1.75/unit for gross proceeds of $9.0M.

• August 18, 2025, 7:59 PM ET other materiality 0.05 neutral item 8.01

  Citius Oncology files prospectus supplement to update S-1 registration statement following 10-Q filing

  Prospectus supplement filed August 18, 2025; original S-1 effective July 15, 2025.

• August 12, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Citius Oncology reports Q3 net loss $5.4M; LYMPHIR launch on track for Q4 2025

  Net loss of $5.4M ($0.08/share) for fiscal Q3 ended June 30, 2025, vs $4.8M ($0.07) a year ago.

• July 18, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Citius Oncology closes $9.0M public offering of 6.82M shares & warrants

  Priced 6,818,182 units at $1.32 each, each consisting of 1 share + 1 warrant for 1 common share.

• June 27, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

  Citius Oncology regains Nasdaq minimum bid price compliance

  Received Nasdaq compliance notice on June 26, 2025, for Listing Rule 5550(a)(2).

• June 17, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology nearing commercial launch of LYMPHIR for CTCL in H2 2025

  Commercial-scale manufacturing completed; inventory sufficient for 12-18 months post-launch with 60-month shelf life.

• May 14, 2025, 7:59 PM ET earnings materiality 0.90 negative item 2.02item 9.01

  Citius Oncology Q2 net loss widens to $7.7M; cash only $112, needs funding beyond May 2025

  Net loss of $7.7M ($0.11 per share) vs $4.8M loss a year ago; R&D and G&A expenses increased due to launch activities.

• April 25, 2025, 7:59 PM ET other material materiality 0.75 negative item 3.01

  Citius Oncology receives Nasdaq deficiency notice for bid price below $1.00

  Nasdaq notified Citius Oncology that its common stock bid price closed below $1.00 for 30 consecutive business days.

• April 3, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 9.01

  Citius Oncology restructures $14.1M payment obligation to Eisai for LYMPHIR milestone and development costs

  Total owed: $5.9M milestone payment plus $8.23M in development and inventory costs.

• February 14, 2025, 6:59 PM ET earnings materiality 0.75 negative item 8.01item 2.02item 9.01

  Citius Oncology reports wider Q1 net loss of $6.7M; engaged Jefferies for strategic alternatives

  Net loss of $6.7M ($0.09/share) vs $4.7M ($0.07) in Q1 fiscal 2024.

• February 6, 2025, 6:59 PM ET regulatory materiality 0.60 positive item 8.01item 9.01

  LYMPHIR assigned permanent J-code J9161 by CMS, effective April 1, 2025

  LYMPHIR (denileukin diftitox-cxdl) received permanent HCPCS J-code J9161 for IV use, 1 microgram.

• January 7, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology provides LYMPHIR launch update; commercialization planned for H1 2025

  LYMPHIR (immunotherapy for CTCL) approved Aug 2024; launch targeted for first half of 2025.

• January 6, 2025, 6:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  Citius Oncology retains Jefferies to explore strategic alternatives including sale or licensing

  Jefferies LLC appointed as exclusive financial advisor to assist in evaluating strategic alternatives.

• December 27, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Citius Oncology full-year net loss widens to $21.1M; FDA-approved LYMPHIR launch on track for H1 2025

  Net loss $21.1M ($0.31/sh) vs $12.7M ($0.19/sh) for FY ended Sep 30, 2024.

• November 12, 2024, 6:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  Citius Oncology reports 27% ORR, 33% CBR in Phase I trial of LYMPHIR + pembrolizumab for recurrent solid tumors

  27% objective response rate (4/15 evaluable) and 33% clinical benefit rate (5/15) in heavily pre-treated gynecologic tumors.

• September 13, 2024, 7:59 PM ET other materiality 0.50 neutral item 1.01

  Citius Oncology secures partial deferral of milestone payment to Dr. Reddy's without penalty

  Milestone payment triggered by FDA approval of LYMPHIR was due Sept 9, 2024; partial deferral granted without penalty.

• September 5, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology's LYMPHIR added to NCCN Guidelines (Category 2A) for CTCL

  LYMPHIR (denileukin diftitox-cxdl) included in NCCN Guidelines for relapsed/refractory Cutaneous T-cell Lymphoma as Category 2A recommendation.

• August 26, 2024, 7:59 PM ET other material materiality 0.80 negative item 2.01item 9.01

  SpinCo reports $14.3M net loss for nine months; going concern uncertainty raised

  Net loss of $14.3M for nine months ended June 30, 2024 (vs $7.5M prior year); no revenue.

• August 16, 2024, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 2.01item 5.06item 9.01item 5.02item 3.02item 3.03item 4.01item 5.01item 5.03 ◈ executive_change ×4

  Citius Oncology completes de-SPAC business combination; CTOR begins trading

  Citius Pharma received 65.6M shares (~92.6% ownership); 4.3M SPAC shares redeemed for ~$49.3M ($11.47 each).

• August 5, 2024, 7:59 PM ET other material materiality 0.85 neutral item 5.02item 5.07item 8.01item 9.01

  TenX Keane shareholders approve business combination with Citius Oncology; redemptions total $49.3M

  All eight proposals approved, including business combination, domestication to Delaware, name change to Citius Oncology, and 15M-share stock incentive plan.

• July 19, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03item 9.01

  TenX Keane Acquisition extends business combination deadline to August 18, 2024 via $66,667 note from Citius Pharma

  Citius Pharma deposited $66,667 into trust to extend deadline from July 18 to August 18, 2024; fourth monthly extension.

• June 18, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03item 9.01

  TenX Keane extends SPAC deadline to July 18 with $66,667 Citius Pharma deposit

  Citius Pharma deposited $66,667 into TenX Keane trust account to extend business combination timeline from June 18 to July 18, 2024.

• June 6, 2024, 7:59 PM ET other material materiality 0.25 neutral item 8.01

  TenX Keane pays additional $268,645 to redeeming shareholders after redemption price miscalculation

  Holders of 2,287,923 shares redeemed at $10.90/share on Jan 17, 2024, for ~$24.9M.

• May 21, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 2.03item 9.01

  TenX Keane Acquisition extends deadline to June 18, 2024 via $66,667 deposit from Citius Pharma

  Citius Pharma deposited $66,667 on May 17, 2024 to extend business combination deadline from May 18 to June 18, 2024.

• April 29, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings

  TenX Keane Acquisition extends business combination deadline to May 18, 2024 with $66,667 deposit

  Citius Pharma deposited $66,667 into trust to extend deadline from April 18 to May 18, 2024.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

17 positive 5 negative 18 neutral

source · CTOR on sec.gov